TPCN2 and breast carcinoma: Carriage of TPCN2 rs35264875:TA or rs72932540:GA or P2RX4 rs28360472:GA was associated with a higher general risk of developing breast cancer (OR: 1.06, 95% CI: 1.02–1.1, P = 0.006**, OR: 1.1, 95% CI: 1.05–1.16, P = 7.2e−05***, OR: 1.1, 95% CI: 1–1.22, P = 0.0478*, respectively, vs. A/A).